TG Therapeutics (NASDAQ:TGTX) Trading Up 6.8% – Should You Buy?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) shot up 6.8% during trading on Friday . The stock traded as high as $30.63 and last traded at $31.03. 1,194,353 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 2,698,843 shares. The stock had previously closed at $29.04.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TGTX shares. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Price Performance

The stock has a market cap of $4.87 billion, a PE ratio of -312.57 and a beta of 2.24. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company’s fifty day moving average is $31.54 and its 200 day moving average is $26.03.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock worth $781,497 over the last 90 days. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Precision Wealth Strategies LLC acquired a new position in TG Therapeutics in the fourth quarter worth about $530,000. Symphony Financial Ltd. Co. bought a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $324,000. Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics during the 4th quarter valued at approximately $75,000. Parkwoods Wealth Partners LLC bought a new position in TG Therapeutics during the fourth quarter worth $211,000. Finally, KBC Group NV boosted its holdings in TG Therapeutics by 48.9% in the fourth quarter. KBC Group NV now owns 6,960 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 2,285 shares during the period. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.